Anti Tissue Transglutaminase-A ELISA (Anti-tTg-A ELISA)
$520.00
Catalog
35-TGAHU-E01
The Anti-tTG-A ELISA is a solid phase enzyme immunoassay for the quantitative and qualitative detection of antibodies against neo-epitopes of tissue transglutaminase (tTG) in human serum. The assay employing human recombinant transglutaminase crosslinked with gliadin-specific peptides displays neo-epitopes of tTG which ensures a significantly increased sensitivity and specificity of the test. The assay is a tool for the diagnosis of celiac disease (gluten-sensitive enteropathy)
FDA Registered. For In Vitro Diagnostic Use.
Minimum Order May be Required. Please call for details.
Gluten-sensitive enteropathy or celiac disease is characterized by atrophy of the small intestinal villi leading to a so-called flat mucosa. It is caused by a pathological intolerance to gliadin, the alcohol-soluble fraction of gluten in wheat, rye, and barley. As celiac disease is caused by the uptake of gluten, consequently a gluten-free diet cures the disease completely and thus has to be maintained for a lifetime. Renewed consumption of gliadin leads to a return of the symptoms. The disease is HLAassociated (>95% of patients have DQ2 enREFd by DQA1*0501 and DQB1*0201) and manifests at any age with a peak onset in early childhood, even in neonatals. The incidence rates range from 1 in 4000 to 1 in 300 in European countries.
Diagnosis of celiac disease is made by small intestinal biopsy (demonstrating flat mucosa) supported by serological markers. Antibodies against gliadin and anti-endomysial antibodies (EMA) are of major significance. They are detected so far by indirect immunofluorescence, which is restricted to subclass IgA only. The identification of tissue transglutaminase (tTG) as the major target antigen of EMA provided the opportunity of a more easy and reliable diagnosis of celiac disease. tTG is an enzyme that upon wounding is released from cells where it is thought to aid in tissue repair.
Anti-tTG antibodies show higher sensitivity and specificity than anti-gliadin antibodies. Furthermore, they correlate tightly with the activity of the disease and thus are especially useful for diet monitoring. The cross-link of tTG with gliadin-specific peptides results in neoepitopes of tTG. As these neoepitopes are structurally closer to the physiological antigens, the new generation Anti-tTG-A ELISAtests show a markedly increased sensitivity and specificity. These epitopes show no cross-reactivities with gliadin.
The determination of IgG antibodies to tTG is the only available specific serology for those 2% to 5% of patients with IgA deficiency. A high number of subclinical cases have been detected by screening for anti-tTG, fostering the theory that the majority of celiac disease cases is undetected and untreated (Iceberg model).
1. What percentage of your IgE allergy testing panel consists of molecular allergens rather than allergen extracts? The ALEX2 IgE allergen panel consists of 117 extracts and 183 molecular allergens. This represents the largest panel of molecular allergens on the market, including 50 unique...
Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives,...
Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food...
Salem, NH, April 25, 2024 – Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the...
ALPCO offers targeted GI solutions suitable for all types of labs. Our offerings range from plate-based to clinical chemistry analyzer-based and automated flash chemiluminescence solutions, all designed to accommodate your lab’s expanding testing needs and capabilities.
In the webinar, Dr. Benjamin Click from the University of Colorado, Department of Gastroenterology, underscores the critical role of non-invasive monitoring methods, particularly fecal calprotectin monitoring, in guiding treatment adjustments and achieving therapeutic goals..
Energy homeostasis is a focus of research into diabetes and obesity. Read about how our assays in this area can assist both academic and industry researchers.
Complement System Solutions for Drug Development and Clinical Research Datasheet
The complement system is essential to innate immunity from a variety of diseases. ALPCO’s full range of complement system immunoassays can drive discovery.
Melatonin Products for Sleep Disorder-Related Research Datasheet
The melatonin hormone affects the circadian rhythm and sleep-wake cycle. Find out about our immunoassays and products that explore melatonin and sleep disorders.